{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:24:06Z","timestamp":1795119846545,"version":"4.10.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence\u00a0(mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensively regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, lower infiltration of cytotoxic T cells (CTLs)\u00a0and anti-tumor helper T cells\u00a0(Th), higher infiltration of regulatory T cells\u00a0(Tregs), decreased T cell clonality, and lower frequencies of top T cell clones in later-stages. Driver mutations, chromosomal copy number aberrations (CNAs)\u00a0and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive ADC.<\/jats:p>","DOI":"10.1038\/s41467-021-22890-x","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T06:04:54Z","timestamp":1620713094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features"],"prefix":"10.1038","volume":"12","author":[{"given":"Hitoshi","family":"Dejima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-6730","authenticated-orcid":false,"given":"Jiexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-1636","authenticated-orcid":false,"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7907-9609","authenticated-orcid":false,"given":"Shawna M.","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzifa","family":"Duose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa M.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-1994","authenticated-orcid":false,"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-4486","authenticated-orcid":false,"given":"Hoa H. N.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mcgranahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latasha","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Gumbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Wan","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Roberto","family":"Estecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna C. B.","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-9537","authenticated-orcid":false,"given":"Mara B.","family":"Antonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-9860","authenticated-orcid":false,"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scheet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-9214","authenticated-orcid":false,"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-8338","authenticated-orcid":false,"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-0382","authenticated-orcid":false,"given":"Alexandre","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Kadara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-3477","authenticated-orcid":false,"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"22890_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. New Engl. J. Med. 382, 503\u2013513 (2020).","journal-title":"New Engl. J. Med."},{"key":"22890_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/ajcp\/111.5.610","volume":"111","author":"H Kitamura","year":"1999","unstructured":"Kitamura, H., Kameda, Y., Ito, T. & Hayashi, H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am. J. Clin. Pathol. 111, 610\u2013622 (1999).","journal-title":"Am. J. Clin. Pathol."},{"key":"22890_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/JTO.0b013e3181ce3b73","volume":"5","author":"AM Maeshima","year":"2010","unstructured":"Maeshima, A. M. et al. Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J. Thorac. Oncol. 5, 466\u2013471 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"22890_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis, W. D. et al. International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244\u2013285 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"22890_CR5","first-page":"7950","volume":"61","author":"Y Aoyagi","year":"2001","unstructured":"Aoyagi, Y. et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res. 61, 7950\u20137954 (2001).","journal-title":"Cancer Res."},{"key":"22890_CR6","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-17-1605","volume":"77","author":"S Sivakumar","year":"2017","unstructured":"Sivakumar, S. et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res. 77, 6119\u20136130 (2017).","journal-title":"Cancer Res."},{"key":"22890_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10877-8","volume":"10","author":"X Hu","year":"2019","unstructured":"Hu, X. et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat. Commun. 10, 2978 (2019).","journal-title":"Nat. Commun."},{"key":"22890_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20907-z","volume":"12","author":"X Hu","year":"2021","unstructured":"Hu, X. et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat. Commun. 12, 687 (2021).","journal-title":"Nat. Commun."},{"key":"22890_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"22890_CR10","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/0008-5472.CAN-14-0037-T","volume":"74","author":"DR Soto-Pantoja","year":"2014","unstructured":"Soto-Pantoja, D. R. et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 74, 6771\u20136783 (2014).","journal-title":"Cancer Res."},{"key":"22890_CR11","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda, E., Ohaegbulam, K. C. & Zang, X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin. Cancer Res. 22, 3425\u20133431 (2016).","journal-title":"Clin. Cancer Res."},{"key":"22890_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"22890_CR13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/onc.2012.269","volume":"32","author":"J Bastid","year":"2013","unstructured":"Bastid, J. et al. ENTPD1\/CD39 is a promising therapeutic target in oncology. Oncogene 32, 1743\u20131751 (2013).","journal-title":"Oncogene"},{"key":"22890_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/322831a0","volume":"322","author":"J Tschopp","year":"1986","unstructured":"Tschopp, J., Masson, D. & Stanley, K. K. Structural\/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature 322, 831\u2013834 (1986).","journal-title":"Nature"},{"key":"22890_CR15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.immuni.2014.11.012","volume":"41","author":"MD Prakash","year":"2014","unstructured":"Prakash, M. D. et al. Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. Immunity 41, 960\u2013972 (2014).","journal-title":"Immunity"},{"key":"22890_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"22890_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"22890_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan, L., Lu, M. P., Wang, J. H., Xu, M. & Yang, S. R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J. Pediatr. 16, 19\u201330 (2020).","journal-title":"World J. Pediatr."},{"key":"22890_CR19","doi-asserted-by":"crossref","unstructured":"Li, T., et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","DOI":"10.1093\/nar\/gkaa407"},{"key":"22890_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul, M. & Ohashi, P. S. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 30, 695\u2013704 (2020).","journal-title":"Trends Cell Biol."},{"key":"22890_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"22890_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267\u20131284 (2018).","journal-title":"Genes Dev."},{"key":"22890_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2007.06.039","volume":"120","author":"CB Schmidt-Weber","year":"2007","unstructured":"Schmidt-Weber, C. B., Akdis, M. & Akdis, C. A. TH17 cells in the big picture of immunology. J. Allergy Clin. Immunol. 120, 247\u2013254 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"22890_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1471-4906(01)01975-5","volume":"22","author":"D Jankovic","year":"2001","unstructured":"Jankovic, D., Liu, Z. & Gause, W. C. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22, 450\u2013457 (2001).","journal-title":"Trends Immunol."},{"key":"22890_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","volume":"222","author":"R Kennedy","year":"2008","unstructured":"Kennedy, R. & Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222, 129\u2013144 (2008).","journal-title":"Immunol. Rev."},{"key":"22890_CR26","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-17-0256","volume":"7","author":"A Reuben","year":"2017","unstructured":"Reuben, A. et al. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov. 7, 1088\u20131097 (2017).","journal-title":"Cancer Discov."},{"key":"22890_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cmi.2010.56","volume":"8","author":"W Shah","year":"2011","unstructured":"Shah, W. et al. A reversed CD4\/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+ FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 8, 59\u201366 (2011).","journal-title":"Cell. Mol. Immunol."},{"key":"22890_CR28","doi-asserted-by":"crossref","unstructured":"Aversa, I., Malanga, D., Fiume, G. & Palmieri, C. Molecular T-cell repertoire analysis as source of prognostic and predictive biomarkers for checkpoint blockade immunotherapy. Int. J. Mol. Sci. 21, 2378 (2020).","DOI":"10.3390\/ijms21072378"},{"key":"22890_CR29","doi-asserted-by":"crossref","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","DOI":"10.1126\/science.aaf8399"},{"key":"22890_CR30","doi-asserted-by":"crossref","unstructured":"Lee, W. C. et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 21, 271 (2020).","DOI":"10.1186\/s13059-020-02175-0"},{"key":"22890_CR31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e1211 (2017).","journal-title":"Cell"},{"key":"22890_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Johnson, B. A. III, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"22890_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"22890_CR34","doi-asserted-by":"publisher","first-page":"e23332","DOI":"10.1371\/journal.pone.0023332","volume":"6","author":"F Ohka","year":"2011","unstructured":"Ohka, F. et al. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 6, e23332 (2011).","journal-title":"PLoS ONE"},{"key":"22890_CR35","first-page":"107","volume":"276","author":"K Kankava","year":"2018","unstructured":"Kankava, K., et al. Line-1 methylation in blood and tissues of patients with breast cancer. Georgian Med. News 276, 107\u2013112 (2018).","journal-title":"Georgian Med. News"},{"key":"22890_CR36","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1158\/1078-0432.CCR-09-2819","volume":"16","author":"K Saito","year":"2010","unstructured":"Saito, K. et al. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin. Cancer Res. 16, 2418\u20132426 (2010).","journal-title":"Clin. Cancer Res."},{"key":"22890_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14273-0","volume":"11","author":"A Reuben","year":"2020","unstructured":"Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).","journal-title":"Nat. Commun."},{"key":"22890_CR38","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.athoracsur.2010.08.016","volume":"90","author":"M Bellomi","year":"2010","unstructured":"Bellomi, M. et al. Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules. Ann. Thorac. Surg. 90, 1759\u20131764 (2010).","journal-title":"Ann. Thorac. Surg."},{"key":"22890_CR39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1056\/NEJMoa1214726","volume":"369","author":"A McWilliams","year":"2013","unstructured":"McWilliams, A. et al. Probability of cancer in pulmonary nodules detected on first screening CT. New Engl. J. Med. 369, 910\u2013919 (2013).","journal-title":"New Engl. J. Med."},{"key":"22890_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cllc.2013.04.005","volume":"14","author":"N Tomonaga","year":"2013","unstructured":"Tomonaga, N. et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin. Lung Cancer 14, 521\u2013526 (2013).","journal-title":"Clin. Lung Cancer"},{"key":"22890_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","volume":"121","author":"R Kim","year":"2007","unstructured":"Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1\u201314 (2007).","journal-title":"Immunology"},{"key":"22890_CR42","doi-asserted-by":"crossref","unstructured":"Lavin, Y., et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750\u2013765.e717 (2014).","DOI":"10.1016\/j.cell.2017.04.014"},{"key":"22890_CR43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","volume":"571","author":"C Mascaux","year":"2019","unstructured":"Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570\u2013575 (2019).","journal-title":"Nature"},{"key":"22890_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3816\/CLC.2003.n.021","volume":"5","author":"S Ballaz","year":"2003","unstructured":"Ballaz, S. & Mulshine, J. L. The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer 5, 46\u201362 (2003).","journal-title":"Clin. Lung Cancer"},{"key":"22890_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1940-6207.CAPR-17-0402","volume":"12","author":"AR Galbraith","year":"2019","unstructured":"Galbraith, A. R. et al. Chemoprevention of lung carcinogenesis by dietary nicotinamide and inhaled budesonide. Cancer Prev. Res. 12, 69\u201378 (2019).","journal-title":"Cancer Prev. Res."},{"key":"22890_CR46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1164\/rccm.200608-1125OC","volume":"175","author":"T Parimon","year":"2007","unstructured":"Parimon, T. et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 712\u2013719 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"22890_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/PPO.0000000000000491","volume":"26","author":"A Gavralidis","year":"2020","unstructured":"Gavralidis, A. & Gainor, J. F. Immunotherapy in EGFR-mutant and ALK-positive lung cancer: implications for oncogene-driven lung cancer. Cancer J. 26, 517\u2013524 (2020).","journal-title":"Cancer J."},{"key":"22890_CR48","unstructured":"Thorsson, V., et al. The immune landscape of cancer. Immunity 48, 812\u2013830.e814 (2018)."},{"key":"22890_CR49","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s\u2013Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"22890_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/path.4832","volume":"241","author":"M Liu","year":"2017","unstructured":"Liu, M., Zhou, J., Chen, Z. & Cheng, A. S. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. J. Pathol. 241, 10\u201324 (2017).","journal-title":"J. Pathol."},{"key":"22890_CR51","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3390\/cancers3021672","volume":"3","author":"A Serrano","year":"2011","unstructured":"Serrano, A., Castro-Vega, I. & Redondo, M. Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers 3, 1672\u20131690 (2011).","journal-title":"Cancers"},{"key":"22890_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.1083557","volume":"300","author":"A Eden","year":"2003","unstructured":"Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).","journal-title":"Science"},{"key":"22890_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/25779","volume":"395","author":"RZ Chen","year":"1998","unstructured":"Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L. & Jaenisch, R. DNA hypomethylation leads to elevated mutation rates. Nature 395, 89\u201393 (1998).","journal-title":"Nature"},{"key":"22890_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung, H. et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat. Commun. 10, 4278 (2019).","journal-title":"Nat. Commun."},{"key":"22890_CR55","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood-2004-07-2583","volume":"105","author":"K Fischer","year":"2005","unstructured":"Fischer, K. et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8\u2013 double-negative regulatory T cells. Blood 105, 2828\u20132835 (2005).","journal-title":"Blood"},{"key":"22890_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s001090100238","volume":"79","author":"ZX Zhang","year":"2001","unstructured":"Zhang, Z. X., Young, K. & Zhang, L. C. D. 3 CD4\u2013CD8\u2013 alphabeta-TCR+ T cell as immune regulatory cell. J. Mol. Med. 79, 419\u2013427 (2001).","journal-title":"J. Mol. Med."},{"key":"22890_CR57","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/77513","volume":"6","author":"ZX Zhang","year":"2000","unstructured":"Zhang, Z. X., Yang, L., Young, K. J., DuTemple, B. & Zhang, L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 6, 782\u2013789 (2000).","journal-title":"Nat. Med."},{"key":"22890_CR58","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.1128\/JVI.00332-11","volume":"85","author":"C Vinton","year":"2011","unstructured":"Vinton, C. et al. CD4\u2013like immunological function by CD4\u2212 T cells in multiple natural hosts of simian immunodeficiency virus. J. Virol. 85, 8702\u20138708 (2011).","journal-title":"J. Virol."},{"key":"22890_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1189\/jlb.1RU0814-382","volume":"97","author":"NH Overgaard","year":"2015","unstructured":"Overgaard, N. H., Jung, J. W., Steptoe, R. J. & Wells, J. W. CD4+\/CD8+ double-positive T cells: more than just a developmental stage? J. Leukoc. Biol. 97, 31\u201338 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"22890_CR60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1256930","volume":"346","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256\u2013259 (2014).","journal-title":"Science"},{"key":"22890_CR61","doi-asserted-by":"publisher","first-page":"21994","DOI":"10.18632\/oncotarget.15777","volume":"8","author":"K Quek","year":"2017","unstructured":"Quek, K. et al. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8, 21994\u201322002 (2017).","journal-title":"Oncotarget"},{"key":"22890_CR62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41379-018-0029-3","volume":"31","author":"WC Lee","year":"2018","unstructured":"Lee, W. C. et al. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod. Pathol. 31, 947\u2013955 (2018).","journal-title":"Mod. Pathol."},{"key":"22890_CR63","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J. Thorac. Oncol. 14, 1912\u20131923 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"22890_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-7-3","volume":"7","author":"A Schroeder","year":"2006","unstructured":"Schroeder, A. et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7, 3 (2006).","journal-title":"BMC Mol. Biol."},{"key":"22890_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano, A. nCounter(\u00ae) PanCancer immune profiling panel (NanoString Technologies, Inc., Seattle, WA). J. Immunother. Cancer 3, 42 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"22890_CR66","first-page":"Unit25B.10","volume":"Chapter 25","author":"MM Kulkarni","year":"2011","unstructured":"Kulkarni, M. M. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr. Protoc. Mol. Biol. Chapter 25, Unit25B.10 (2011).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"22890_CR67","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/bioinformatics\/btg148","volume":"19","author":"S Pounds","year":"2003","unstructured":"Pounds, S. & Morris, S. W. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19, 1236\u20131242 (2003).","journal-title":"Bioinformatics"},{"key":"22890_CR68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"22890_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 17, 174 (2016).","journal-title":"Genome Biol."},{"key":"22890_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-018-0368-0","volume":"6","author":"ER Parra","year":"2018","unstructured":"Parra, E. R. et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J. Immunother. Cancer 6, 48 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"22890_CR71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/978-1-4939-9773-2_22","volume":"2055","author":"A Francisco-Cruz","year":"2020","unstructured":"Francisco-Cruz, A., Parra, E. R., Tetzlaff, M. T., & Wistuba, I. I. Multiplex immunofluorescence assays. Methods Mol. Biol. 2055, 467\u2013495 (2020).","journal-title":"Methods Mol. Biol."},{"key":"22890_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen, M. & Andreatta, M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8, 33 (2016).","journal-title":"Genome Med."},{"key":"22890_CR73","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00251-015-0873-y","volume":"67","author":"M Andreatta","year":"2015","unstructured":"Andreatta, M. et al. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics 67, 641\u2013650 (2015).","journal-title":"Immunogenetics"},{"key":"22890_CR74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate\u2014a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22890-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T12:40:31Z","timestamp":1725021631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22890-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22890"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22890-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.11.20142992","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. I.I.W reports Honoraria from Genentech\/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca\/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Oncocyte, Flame, and MSD; Research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. H.K. reports funding to MD Anderson Cancer Center from Johnson and Johnson. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs.\u00a0The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2722"}}